Full-Time

Logistics Coordinator I

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$39.42 - $42.31Hourly

Entry

San Carlos, CA, USA

Base salary range is for candidates based at headquarters in Redwood City, CA.

Category
Warehouse Operations
Operations & Logistics
Requirements
  • High school diploma or general education degree (GED) and 4 years of related experience; or,
  • AA degree in related discipline and two years of related experience; or,
  • May require certification in assigned area.
Responsibilities
  • responsible for maintaining critical parts for building equipment in support of Revolution Medicines’ Facilities organization.
  • individual contributor with supply inventory responsibilities, reporting to the Director, Facilities.

Revolution Medicines develops targeted treatments for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to specifically inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses exclusively on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

12%

1 year growth

36%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for research and development.
  • Strong investor confidence shown by recent upsized public offering.
  • Growing interest in targeted therapies aligns with their focus on RAS mutations.

What critics are saying

  • EQRx acquisition may lead to integration challenges and cultural clashes.
  • $600M public stock offering could result in shareholder dilution.

What makes Revolution Medicines unique

  • Revolution Medicines uses a unique method to synthesize pharmaceutically optimized natural compounds.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive license with University of Illinois enhances their proprietary technology.

Help us improve and share your feedback! Did you find this helpful?